Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Starpharma Holdings Ltd. (SPHRY : OTC)
 
 • Company Description   
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.

Number of Employees: 50

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.31 Daily Weekly Monthly
20 Day Moving Average: 934 shares
Shares Outstanding: 40.74 (millions)
Market Capitalization: $216.35 (millions)
Beta: 1.71
52 Week High: $13.73
52 Week Low: $5.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.04% -4.32%
12 Week -22.76% -15.10%
Year To Date -44.11% -28.30%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4-6 Southampton Crescent
-
Abbotsford,C3 3072
AUS
ph: 61-3-8532-2700
fax: 61-3-9510-5955
investor.relations@starpharma.com http://www.starpharma.com
 
 • General Corporate Information   
Officers
Jackie Fairley - Chief Executive Officer
R B Thomas - Chairman
Peter R Turvey - Director
David McIntyre - Director
Zita Peach - Director

Peer Information
Starpharma Holdings Ltd. (CORR.)
Starpharma Holdings Ltd. (RSPI)
Starpharma Holdings Ltd. (CGXP)
Starpharma Holdings Ltd. (BGEN)
Starpharma Holdings Ltd. (GTBP)
Starpharma Holdings Ltd. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 855563102
SIC: 8731
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 40.74
Most Recent Split Date: (:1)
Beta: 1.71
Market Capitalization: $216.35 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©